HK StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

PEGBIO CO-B

5.875

-0.100-1.67%

Volume:4.99M

Turnover:29.58M

Market Cap:2.30B

PE:-10.68

High:6.040

Open:5.990

Low:5.870

Close:5.975

52wk High:77.000

52wk Low:4.940

Shares:391.00M

HK Float Shares:386.00M

Volume Ratio:0.36

T/O Rate:1.29%

Dividend:- -

Dividend Rate:- -

EPS(LYR):-0.550

ROE:-82.42%

ROA:-31.46%

PB:4.39

PE(LYR):-10.68

PS:-508.02

Loading ...

Overview Company News Filings

PEGBIO CO-B Receives CSRC Filing Notice for H-Share Full Circulation

PegBio receives CSRC filing notice for H-share full circulation of 101,702,051 shares

PegBio Reports No Share Capital Changes, Confirms Public Float Compliance for March 2026

Bulletin Express

PegBio's CR059 Selection for ADA Late-Breaking Abstract Highlights Monthly-Dosing GLP-1 Potential

PegBio's CR059, a Potential Game-Changer in Metabolic Disease Treatment, Garners Prestigious Recognition at ADA Conference

PegBio Announces ADA 2026 Late-Breaking Abstract Acceptance for Once-Monthly GLP-1 Candidate CR059

Bulletin Express

PEGBIO CO-B's CR059 Research Abstract Accepted for Poster Presentation at ADA 2026 Scientific Sessions

PegBio says CR059 diabetes abstract accepted as ADA late-breaking poster presentation

PEGBIO CO-B Announces Appointment of Guo En-ting as Joint Company Secretary and Authorized Representative

PegBio Announces Company Secretary Reshuffle and Secures HKEX Waiver

Bulletin Express

PegBio appoints Kwok Yan Ting Jennis as joint company secretary, replacing Chow Shing Lung

BRIEF-PegBio Co Posts FY Loss Attributable RMB208.4 Million

PegBio Trims Losses in 2025

MT Newswires Live

PegBio 2025 Annual Results: Net Loss Reduced to RMB208.55 Million, Cash Reserves Reach RMB467.54 Million Following Dual Fund-raisings

Bulletin Express

PEGBIO CO-B Reports Annual Results with R&D Investment of RMB50.387 Million and a Pipeline of Seven Chronic Disease Drug Candidates

Pegbio Co Ltd - FY Loss Attributable RMB208.4 Mln

THOMSON REUTERS

PegBio Wins China Approval for PB-119 Vepinetide Injection###

PegBio FY2025 net loss narrows 26.39% to RMB 208 million, equity jumps 6.81x to RMB 449 million

BUZZ-PegBio jumps most in 7 months on deal with Shanghai Tenry

Hong Kong Market Announcements: Ant Group's Acquisition of Bright Smart Receives Approval, Trading Resumes March 17

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.gotigerhk.com/stock/02565/news?page=5"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"02565","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02565\",,,,,undefined,":{"symbol":"02565","market":"HK","secType":"STK","nameCN":"PEGBIO CO-B","latestPrice":5.875,"timestamp":1787299688008,"preClose":5.975,"halted":0,"volume":4987250,"delay":0,"changeRate":-0.01673640167364011,"floatShares":386000000,"shares":391000000,"eps":-0.55,"marketStatus":"Not Yet Opened","change":-0.1,"latestTime":"08-21 16:08:08","open":5.99,"high":6.04,"low":5.87,"amount":29583125,"amplitude":0.028452,"askPrice":5.9,"askSize":600,"bidPrice":5.875,"bidSize":23100,"shortable":3,"etf":0,"ttmEps":-0.612785,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1787535000000},"marketStatusCode":0,"adr":0,"listingDate":1748275200000,"exchange":"SEHK","adjPreClose":5.975,"openAndCloseTimeList":[[1787275800000,1787284800000],[1787288400000,1787299200000]],"volumeRatio":0.35780179890285707,"lotSize":50,"spreadScale":0,"tradeCurrency":"HKD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02565\",,,,,undefined,":{"symbol":"02565","floatShares":386000000,"roa":"-31.46%","roe":"-82.42%","lyrEps":-0.55,"volumeRatio":0.35780179890285707,"shares":391000000,"dividePrice":0,"high":6.04,"amplitude":0.028452,"preClose":5.975,"low":5.87,"week52Low":4.94,"pbRate":"4.39","psRate":"-508.02","week52High":77,"institutionHeld":0,"latestPrice":5.875,"committee":0.949367,"eps":-0.55,"divideRate":0,"volume":4987250,"delay":0,"ttmEps":-0.612785,"open":5.99,"prevYearClose":69,"prevWeekClose":6.23,"prevMonthClose":5.36,"prevQuarterClose":5.33,"fiveDayClose":6.23,"twentyDayClose":6.39,"sixtyDayClose":8.82,"earningDate":1787587200000},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/02565\",params:#limit:5,,,undefined,":[{"date":"2026-08-25","symbol":"02565","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1787621400000,"name":null,"time":"","dateTimestamp":1787587200000,"actualEps":null},{"market":"HK","date":"2026-03-23","symbol":"02565","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1774195200000,"reportTimeType":"post","actualEps":null},{"date":"2025-08-26","symbol":"02565","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1756171800000,"name":null,"time":"","dateTimestamp":1756137600000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"02565\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"02565\",market:\"HK\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/hkstock/value_analysis/stock/02565\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"02565","date":"2026-08-21","current":-9.587376,"percent":0.935811,"low":-87.782868,"twenty":-72.846173,"median":-58.454271,"eighty":-11.546541,"high":-7.824338,"avg":-44.305288,"sd":28.056716,"marketCap":2297662750},"quantilePoints":[{"date":"2025-05-30","current":-12.743079,"twenty":-15.470266,"median":-13.542645,"eighty":-13.135794,"marketCap":3936746426},{"date":"2025-06-06","current":-11.987888,"twenty":-13.726785,"median":-12.740515,"eighty":-12.114178,"marketCap":3712892217},{"date":"2025-06-13","current":-11.23576,"twenty":-13.295707,"median":-12.114337,"eighty":-11.528404,"marketCap":3481318898},{"date":"2025-06-20","current":-11.30775,"twenty":-12.841258,"median":-11.963331,"eighty":-11.337793,"marketCap":3496757119},{"date":"2025-06-27","current":-12.421214,"twenty":-12.738977,"median":-11.541778,"eighty":-11.292079,"marketCap":3851836209},{"date":"2025-07-04","current":-13.963875,"twenty":-12.971799,"median":-11.987888,"eighty":-11.299391,"marketCap":4330421069},{"date":"2025-07-11","current":-13.604213,"twenty":-13.050401,"median":-12.199189,"eighty":-11.305737,"marketCap":4214634409},{"date":"2025-07-18","current":-16.956264,"twenty":-13.748078,"median":-12.438987,"eighty":-11.330282,"marketCap":5248995235},{"date":"2025-07-25","current":-19.006677,"twenty":-15.472199,"median":-12.742066,"eighty":-11.352726,"marketCap":5905119639},{"date":"2025-08-01","current":-19.199848,"twenty":-18.276271,"median":-12.906561,"eighty":-11.424474,"marketCap":5928276971},{"date":"2025-08-08","current":-20.51103,"twenty":-19.019895,"median":-13.05938,"eighty":-11.472546,"marketCap":6348968501},{"date":"2025-08-15","current":-39.959751,"twenty":-19.179784,"median":-13.542645,"eighty":-11.515029,"marketCap":12350577024},{"date":"2025-08-22","current":-41.864246,"twenty":-19.284777,"median":-13.964282,"eighty":-11.779976,"marketCap":12898633879},{"date":"2025-08-29","current":-41.44792,"twenty":-21.432837,"median":-14.946806,"eighty":-11.968242,"marketCap":10033166343},{"date":"2025-09-05","current":-50.678037,"twenty":-39.039264,"median":-17.018603,"eighty":-12.06328,"marketCap":12255314482},{"date":"2025-09-12","current":-58.538001,"twenty":-40.749762,"median":-18.438762,"eighty":-12.114019,"marketCap":14181548421},{"date":"2025-09-19","current":-57.311117,"twenty":-43.720929,"median":-18.952908,"eighty":-12.216159,"marketCap":13874467648},{"date":"2025-09-26","current":-63.587749,"twenty":-49.33228,"median":-19.070122,"eighty":-12.366345,"marketCap":15354038645},{"date":"2025-10-03","current":-60.149194,"twenty":-54.575673,"median":-19.16943,"eighty":-12.428323,"marketCap":14558420278},{"date":"2025-10-10","current":-60.121463,"twenty":-57.957283,"median":-19.199848,"eighty":-12.49878,"marketCap":14530503844},{"date":"2025-10-17","current":-60.168303,"twenty":-59.756564,"median":-19.2984,"eighty":-12.738571,"marketCap":14530503844},{"date":"2025-10-24","current":-61.301982,"twenty":-60.143648,"median":-20.51103,"eighty":-12.741458,"marketCap":14809668183},{"date":"2025-10-31","current":-69.345185,"twenty":-60.159469,"median":-22.018639,"eighty":-12.743079,"marketCap":16777776773},{"date":"2025-11-07","current":-59.401661,"twenty":-60.392128,"median":-34.33922,"eighty":-12.780248,"marketCap":14363005241},{"date":"2025-11-14","current":-72.819022,"twenty":-61.035505,"median":-39.959751,"eighty":-12.906561,"marketCap":17657144441},{"date":"2025-11-21","current":-72.852961,"twenty":-61.301982,"median":-40.866122,"eighty":-12.943343,"marketCap":17657144441},{"date":"2025-11-28","current":-82.344376,"twenty":-62.346137,"median":-42.423494,"eighty":-13.014482,"marketCap":20030041323},{"date":"2025-12-05","current":-72.063717,"twenty":-63.355663,"median":-45.122001,"eighty":-13.104279,"marketCap":17559436923},{"date":"2025-12-12","current":-74.217813,"twenty":-64.460997,"median":-48.969529,"eighty":-13.233973,"marketCap":18117765601},{"date":"2025-12-19","current":-71.875632,"twenty":-65.413889,"median":-52.055133,"eighty":-13.542645,"marketCap":17587353357},{"date":"2025-12-24","current":-73.927127,"twenty":-69.382811,"median":-55.337969,"eighty":-13.579586,"marketCap":18145682035},{"date":"2026-01-02","current":-79.895405,"twenty":-70.540926,"median":-57.311117,"eighty":-13.748078,"marketCap":19687798475},{"date":"2026-01-09","current":-85.854057,"twenty":-72.056904,"median":-58.941314,"eighty":-13.964201,"marketCap":21208805289},{"date":"2026-01-16","current":-80.413876,"twenty":-72.839385,"median":-59.401661,"eighty":-14.164153,"marketCap":19929453763},{"date":"2026-01-23","current":-77.735339,"twenty":-73.262106,"median":-59.808211,"eighty":-14.656731,"marketCap":19247132950},{"date":"2026-01-30","current":-73.838267,"twenty":-73.550435,"median":-60.0941,"eighty":-15.472199,"marketCap":18365801899},{"date":"2026-02-06","current":-69.490034,"twenty":-73.32273,"median":-60.154331,"eighty":-16.538679,"marketCap":17328105662},{"date":"2026-02-13","current":-71.473742,"twenty":-73.562339,"median":-60.192909,"eighty":-17.006135,"marketCap":17925136373},{"date":"2026-02-20","current":-71.065981,"twenty":-73.716985,"median":-60.392128,"eighty":-17.056006,"marketCap":17797201221},{"date":"2026-02-27","current":-72.540901,"twenty":-73.438012,"median":-60.796223,"eighty":-17.950543,"marketCap":18365801899},{"date":"2026-03-06","current":-68.036226,"twenty":-73.352041,"median":-61.160082,"eighty":-18.384598,"marketCap":17086450373},{"date":"2026-03-13","current":-60.794114,"twenty":-73.299371,"median":-60.919795,"eighty":-18.597951,"marketCap":15338003289},{"date":"2026-03-20","current":-67.303035,"twenty":-73.275932,"median":-61.206433,"eighty":-18.84686,"marketCap":16915870170},{"date":"2026-03-27","current":-68.867925,"twenty":-73.269478,"median":-61.274827,"eighty":-18.985169,"marketCap":16247764373},{"date":"2026-04-02","current":-85.055535,"twenty":-73.278872,"median":-61.433108,"eighty":-19.026504,"marketCap":20163286400},{"date":"2026-04-10","current":-78.454069,"twenty":-73.369897,"median":-61.662876,"eighty":-19.045802,"marketCap":18741784705},{"date":"2026-04-17","current":-76.94604,"twenty":-73.948705,"median":-62.45145,"eighty":-19.079188,"marketCap":18389252284},{"date":"2026-04-24","current":-60.4786,"twenty":-73.948705,"median":-62.528681,"eighty":-19.126247,"marketCap":14454535592},{"date":"2026-05-15","current":-17.642518,"twenty":-73.927127,"median":-62.346137,"eighty":-19.115451,"marketCap":4376314243},{"date":"2026-05-22","current":-20.448357,"twenty":-73.838267,"median":-61.433108,"eighty":-19.16943,"marketCap":5060724424},{"date":"2026-05-29","current":-13.590249,"twenty":-73.716985,"median":-61.274827,"eighty":-19.064042,"marketCap":3375119921},{"date":"2026-06-05","current":-12.579887,"twenty":-73.438012,"median":-61.206433,"eighty":-18.597951,"marketCap":3128732256},{"date":"2026-06-12","current":-11.565594,"twenty":-73.352041,"median":-60.919795,"eighty":-17.056006,"marketCap":2874522760},{"date":"2026-06-18","current":-9.622776,"twenty":-73.31105,"median":-60.791238,"eighty":-14.753422,"marketCap":2397391091},{"date":"2026-06-26","current":-7.824338,"twenty":-73.278872,"median":-60.512398,"eighty":-13.899973,"marketCap":1939813998},{"date":"2026-07-03","current":-8.984958,"twenty":-73.271235,"median":-60.431019,"eighty":-13.561687,"marketCap":2229221732},{"date":"2026-07-10","current":-11.252888,"twenty":-73.25947,"median":-60.210807,"eighty":-13.050401,"marketCap":2788482623},{"date":"2026-07-17","current":-10.458113,"twenty":-73.235067,"median":-60.159469,"eighty":-12.830773,"marketCap":2600758687},{"date":"2026-07-24","current":-10.046967,"twenty":-73.215248,"median":-60.107782,"eighty":-12.739192,"marketCap":2499074889},{"date":"2026-07-31","current":-8.411523,"twenty":-73.183292,"median":-59.862622,"eighty":-12.522041,"marketCap":2096250611},{"date":"2026-08-07","current":-10.298244,"twenty":-73.061453,"median":-59.675079,"eighty":-12.306772,"marketCap":2571426822},{"date":"2026-08-14","current":-9.745542,"twenty":-72.966779,"median":-59.367669,"eighty":-11.991332,"marketCap":2436500244},{"date":"2026-08-21","current":-9.169953,"twenty":-72.846173,"median":-58.454271,"eighty":-11.546541,"marketCap":2297662750}],"updateTime":1787511614413},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"02565\",pageSize:20,pageCount:5,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1151031921","title":"PEGBIO CO-B Receives CSRC Filing Notice for H-Share Full Circulation","url":"https://stock-news.laohu8.com/highlight/detail?id=1151031921","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1151031921?lang=en_us&edition=fundamental","pubTime":"2026-04-09 18:30","pubTimestamp":1775730638,"startTime":"0","endTime":"0","summary":"PEGBIO CO-B (02565) has announced that the company has received a filing notice from the China Securities Regulatory Commission (CSRC) dated March 26, 2026, regarding the implementation of an H-share...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["161726","BK4588","XBI","BK1161","02565","BK4581","BK4585","399441"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626888185","title":"PegBio receives CSRC filing notice for H-share full circulation of 101,702,051 shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2626888185","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626888185?lang=en_us&edition=fundamental","pubTime":"2026-04-09 18:26","pubTimestamp":1775730395,"startTime":"0","endTime":"0","summary":"PegBio received a filing notice dated March 26, 2026 from China securities regulator for its H-share full circulation plan.Filing covers conversion of 101,702,051 unlisted shares into H shares.PegBio plans to seek Hong Kong listing approval to allow trading of converted H shares on Main Board.Conversion must be completed within 12 months of March 26, 2026 or the filing will need to be refreshed.Implementation plan remains unfinished, with further updates expected as process advances.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pegbio Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on April 09, 2026, and is solely responsible ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260409:nNDLc8wwBW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02565","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1183616961","title":"PegBio Reports No Share Capital Changes, Confirms Public Float Compliance for March 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=1183616961","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1183616961?lang=en_us&edition=fundamental","pubTime":"2026-04-08 17:22","pubTimestamp":1775640134,"startTime":"0","endTime":"0","summary":"PegBio Co., Ltd. (PEGBIO CO-B) submitted its Monthly Return for Equity Issuer, covering the period ended 31 March 2026, with the following highlights: • Share Capital Stability: Registered share...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02565"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1184512860","title":"PegBio's CR059 Selection for ADA Late-Breaking Abstract Highlights Monthly-Dosing GLP-1 Potential","url":"https://stock-news.laohu8.com/highlight/detail?id=1184512860","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1184512860?lang=en_us&edition=fundamental","pubTime":"2026-04-07 19:02","pubTimestamp":1775559779,"startTime":"0","endTime":"0","summary":"PegBio (02565) has drawn market attention back to its circRNA-LNP technology platform after its core pipeline candidate CR059 was selected as a Late-Breaking Abstract (LBA) for the American Diabetes...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4590","GLP","BK1161","02565","BK4144"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1134240360","title":"PegBio's CR059, a Potential Game-Changer in Metabolic Disease Treatment, Garners Prestigious Recognition at ADA Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=1134240360","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1134240360?lang=en_us&edition=fundamental","pubTime":"2026-04-02 20:07","pubTimestamp":1775131625,"startTime":"0","endTime":"0","summary":"PegBio CO-B (02565) announced after market close on April 2nd that a research abstract for its self-developed innovative drug candidate, CR059, has been accepted for presentation at the American...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02565","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1134587484","title":"PegBio Announces ADA 2026 Late-Breaking Abstract Acceptance for Once-Monthly GLP-1 Candidate CR059","url":"https://stock-news.laohu8.com/highlight/detail?id=1134587484","media":"Bulletin Express","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1134587484?lang=en_us&edition=fundamental","pubTime":"2026-04-02 19:25","pubTimestamp":1775129108,"startTime":"0","endTime":"0","summary":"PegBio Co., Ltd. reported that its internally developed candidate CR059 has been accepted as a Late Breaking Abstract for poster presentation at the 2026 Scientific Sessions of the American Diabetes...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02565"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1179308864","title":"PEGBIO CO-B's CR059 Research Abstract Accepted for Poster Presentation at ADA 2026 Scientific Sessions","url":"https://stock-news.laohu8.com/highlight/detail?id=1179308864","media":"Stock News","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1179308864?lang=en_us&edition=fundamental","pubTime":"2026-04-02 19:20","pubTimestamp":1775128824,"startTime":"0","endTime":"0","summary":"PEGBIO CO-B (02565) announced that a research abstract related to its self-developed innovative candidate product, CR059, has been accepted by the American Diabetes Association (ADA) for its 2026...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","399441","BK1161","XBI","161726","BK4588","02565","BK4581"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624503124","title":"PegBio says CR059 diabetes abstract accepted as ADA late-breaking poster presentation","url":"https://stock-news.laohu8.com/highlight/detail?id=2624503124","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624503124?lang=en_us&edition=fundamental","pubTime":"2026-04-02 19:12","pubTimestamp":1775128357,"startTime":"0","endTime":"0","summary":"PegBio disclosed that an abstract on CR059 was accepted for poster presentation at 2026 American Diabetes Association Scientific Sessions as a late-breaking abstract.Results have not yet been presented; presentation is scheduled during 2026 ADA meeting.Preclinical data in rhesus monkeys with type 2 diabetes showed durable glycemic control with weight-loss effects, supporting potential for long-acting metabolic disease treatment.Management highlighted expected monthly dosing potential, with a path to quarterly dosing, based on circRNA-LNP platform.Update signals rising external validation for PegBio metabolic disease pipeline, with CR059 still in research and development stage.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pegbio Co. L","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260402:nNDLG15Kb:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02565","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1106026379","title":"PEGBIO CO-B Announces Appointment of Guo En-ting as Joint Company Secretary and Authorized Representative","url":"https://stock-news.laohu8.com/highlight/detail?id=1106026379","media":"Stock News","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1106026379?lang=en_us&edition=fundamental","pubTime":"2026-04-01 19:10","pubTimestamp":1775041812,"startTime":"0","endTime":"0","summary":"PEGBIO CO-B (02565) has announced that Mr. Zou Xinglong has resigned from his positions as Joint Company Secretary, Authorized Representative under Rule 3.05 of the Hong Kong Stock Exchange Listing...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4581","161726","02565","BK4588","BK4585","XBI","399441","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1100737065","title":"PegBio Announces Company Secretary Reshuffle and Secures HKEX Waiver","url":"https://stock-news.laohu8.com/highlight/detail?id=1100737065","media":"Bulletin Express","labels":["executive","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1100737065?lang=en_us&edition=fundamental","pubTime":"2026-04-01 19:04","pubTimestamp":1775041467,"startTime":"0","endTime":"0","summary":"PegBio Co., Ltd. has disclosed a senior management change effective 1 April 2026. Joint Company Secretary, Authorised Representative and Process Agent Mr. Chow Shing Lung will step down, citing no...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02565"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624289597","title":"PegBio appoints Kwok Yan Ting Jennis as joint company secretary, replacing Chow Shing Lung","url":"https://stock-news.laohu8.com/highlight/detail?id=2624289597","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624289597?lang=en_us&edition=fundamental","pubTime":"2026-04-01 19:02","pubTimestamp":1775041346,"startTime":"0","endTime":"0","summary":"PegBio appointed Kwok Yan Ting Jennis as joint company secretary, authorized representative, process agent effective April 1, 2026.Kwok is senior manager, Entity Solutions at Computershare Hong Kong Investor Services with more than 12 years’ experience in corporate governance, company secretarial practice, regulatory compliance.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pegbio Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on April 01, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260401:nNDL9mQGfS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CPU.AU","BK7157","BK1161","BK7033","02565","BK7503"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621775537","title":"BRIEF-PegBio Co Posts FY Loss Attributable RMB208.4 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2621775537","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621775537?lang=en_us&edition=fundamental","pubTime":"2026-03-23 18:49","pubTimestamp":1774262958,"startTime":"0","endTime":"0","summary":"BRIEF-PegBio Co Posts FY Loss Attributable RMB208.4 MillionMarch 23 (Reuters) - PegBio Co Ltd 2565.HK:FY LOSS ATTRIBUTABLE RMB208.4 MILLIONFurther company coverage: 2565.HK ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260323:nFWN40B05N:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02565"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621779352","title":"PegBio Trims Losses in 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2621779352","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621779352?lang=en_us&edition=fundamental","pubTime":"2026-03-23 17:00","pubTimestamp":1774256439,"startTime":"0","endTime":"0","summary":"PegBio  booked 208.4 million yuan in attributable loss for 2025, narrowing from 283.4 million yuan in 2024, according to a Hong Kong bourse filing Monday.Loss per share was 0.55 yuan, compared with 0.77 yuan in the prior year.The firm did not generate any revenue during the year or in 2024.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["02565","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1191587925","title":"PegBio 2025 Annual Results: Net Loss Reduced to RMB208.55 Million, Cash Reserves Reach RMB467.54 Million Following Dual Fund-raisings","url":"https://stock-news.laohu8.com/highlight/detail?id=1191587925","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1191587925?lang=en_us&edition=fundamental","pubTime":"2026-03-23 16:42","pubTimestamp":1774255349,"startTime":"0","endTime":"0","summary":"PegBio Co., Ltd. (PEGBIO CO-B, 02565) released its audited results for the year ended 31 December 2025. Financial Performance   • Loss for the year narrowed 26.4% to RMB208.55 million, versus...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02565"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1180038614","title":"PEGBIO CO-B Reports Annual Results with R&D Investment of RMB50.387 Million and a Pipeline of Seven Chronic Disease Drug Candidates","url":"https://stock-news.laohu8.com/highlight/detail?id=1180038614","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1180038614?lang=en_us&edition=fundamental","pubTime":"2026-03-23 16:42","pubTimestamp":1774255342,"startTime":"0","endTime":"0","summary":"PEGBIO CO-B (02565) announced its annual results for the period ending December 31, 2025. The Group recorded other net income of RMB189,000 and research and development expenses of RMB50.387 million....","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4581","BK1161","XBI","BK4585","161726","BK4588","02565","399441"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621469775","title":"Pegbio Co Ltd - FY Loss Attributable RMB208.4 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2621469775","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621469775?lang=en_us&edition=fundamental","pubTime":"2026-03-23 16:32","pubTimestamp":1774254727,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260323:nFWN40B05N:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["02565","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621775455","title":"PegBio Wins China Approval for PB-119 Vepinetide Injection###","url":"https://stock-news.laohu8.com/highlight/detail?id=2621775455","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621775455?lang=en_us&edition=fundamental","pubTime":"2026-03-23 16:31","pubTimestamp":1774254699,"startTime":"0","endTime":"0","summary":"Pegbio said its PB-119 product received marketing approval from China’s National Medical Products Administration in November 2025, enabling a shift from development to commercialization planning.The company expects PB-119 to begin commercial sales in 1H 2026, positioning it to become Pegbio’s first revenue-generating product.Pegbio is pursuing a partnership-based commercialization approach in mainland China after a prior marketing collaboration for PB-119 was terminated in June 2025.The company reported no revenue from PB-119 as of the announcement date and ended 2025 with CNY 467.5 million in cash and cash equivalents to support launch execution.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pegbio Co. Ltd. published the original con","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260323:nNDL9pF429:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02565","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621775453","title":"PegBio FY2025 net loss narrows 26.39% to RMB 208 million, equity jumps 6.81x to RMB 449 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2621775453","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621775453?lang=en_us&edition=fundamental","pubTime":"2026-03-23 16:31","pubTimestamp":1774254694,"startTime":"0","endTime":"0","summary":"PegBio published an annual results announcement for the year ended Dec. 31, 2025.Loss from operations narrowed 26.73% to RMB205.77 million, and loss for the year narrowed 26.4% to RMB208.55 million.Basic and diluted loss per share improved 28.57% to RMB0.55, while the company reported no revenue from product sales.Total assets rose more than 1.7x to RMB599.23 million, and cash and cash equivalents rose more than 1.7x to RMB467.54 million.PB-119 received marketing approval from China’s NMPA in November 2025, and PegBio expects commercial sales to begin in the first half of 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pegbio Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Information S","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260323:nNDL7sY1nP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02565","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620741213","title":"BUZZ-PegBio jumps most in 7 months on deal with Shanghai Tenry","url":"https://stock-news.laohu8.com/highlight/detail?id=2620741213","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620741213?lang=en_us&edition=fundamental","pubTime":"2026-03-17 11:34","pubTimestamp":1773718440,"startTime":"0","endTime":"0","summary":"BUZZ-PegBio jumps most in 7 months on deal with Shanghai Tenry** China-based PegBio Co 2565.HK shares jump as much as 20.3% to HK$65.15, set for biggest one-day pct rise since August 15, 2025 ** Innovative therapies developer's stock hit the highest point since March 9** PegBio said it has entered into an exclusive commercialization collaboration with Shanghai Tenry Pharmaceutical for the company's core product Paidakang for treatment of type 2 diabetes in China ** Tenry Pharmaceutical will pay royalty totaling HK$140 million  to the company - Co** YTD, stock down 17.6%, while Hang Seng Biotech Index .HSBIO climbs 3.8%","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260317:nL1N40503X:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02565"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1192730058","title":"Hong Kong Market Announcements: Ant Group's Acquisition of Bright Smart Receives Approval, Trading Resumes March 17","url":"https://stock-news.laohu8.com/highlight/detail?id=1192730058","media":"Stock News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1192730058?lang=en_us&edition=fundamental","pubTime":"2026-03-17 09:18","pubTimestamp":1773710304,"startTime":"0","endTime":"0","summary":"Major Corporate Developments: Hengrui Pharma (01276) announced that its SHR-1819 injection and SHR-1905 injection have received drug clinical trial approval notices. Henlius (02696) disclosed that...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0359201612.USD","LU0359201885.HKD","LU1023057109.AUD","02565","01276","HK0000306701.USD","LU0359202008.SGD","HK0000306685.HKD","BK1606","BK1161","01428","HK0000320264.USD","HK0000320223.HKD","BK1515","HK0000165453.HKD","BK1147","02696","BK1191","06688","BK4588","BK1197","BK4585","00874","LU2543165471.USD","BK1521","VXUS"],"isVideo":false,"video":null,"gpt_icon":1}],"pageSize":20,"totalPage":6,"pageCount":5,"totalSize":115,"code":"91000000","status":"200"}]}}